Gabelli Funds’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Gabelli Funds’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-8,700	Closed	-$452K	–	1232
2022 Q3	$452K	Buy	8,700 +350	+4%	+$17.9K	﹤0.01%	1006
2022 Q2	$466K	Buy	8,350 +1,850	+28%	+$110K	﹤0.01%	1035
2022 Q1	$403K	Hold	6,500	–	–	﹤0.01%	1094
2021 Q4	$358K	Sell	6,500 -500	-7%	-$26.1K	﹤0.01%	1152
2021 Q3	$368K	Buy	7,000 +500	+8%	+$29.7K	﹤0.01%	1127
2021 Q2	$448K	Buy	6,500 +1,000	+18%	+$76.3K	﹤0.01%	1091
2021 Q1	$424K	Buy	+5,500	New	+$507K	﹤0.01%	1080

Other funds holding LKFT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Gabelli Funds's LKFT Position: Q4 2022 in Review

Gabelli Funds sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q4 2022, closing a stake of 8,700 shares — an estimated $452K sold.

Gabelli Funds first reported a position in LKFT in Q1 2021 and held it in 7 quarters. The position peaked at $466K in Q2 2022. 75 funds tracked by Wall St. Rank hold LKFT as of Q4 2022.

Gabelli Funds reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q4 2022 after selling out during the quarter.
Gabelli Funds sold 8,700 Lakefront Biotherapeutics American Depositary Shares shares in Q4 2022, an estimated $452K.
Gabelli Funds first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2021 and held it in 7 quarters.
Gabelli Funds's Lakefront Biotherapeutics American Depositary Shares position peaked at $466K in Q2 2022.
75 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q4 2022.

Based on Gabelli Funds's 13F filing for Q4 2022, filed 13 Feb 2023.